Impact of allopurinol on risk of myocardial infarction. - Wikidata - wikimedia - TriplyDB

Impact of allopurinol on risk of myocardial infarction.

Impact of allopurinol on risk of myocardial infarction.

http://www.wikidata.org/entity/Q39033643

about

Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications Uric acid in metabolic syndrome: From an innocent bystander to a central player Hyperuricaemia with deposition: latest evidence and therapeutic approach Molecular Characterization of Reactive Oxygen Species in Myocardial Ischemia-Reperfusion Injury Review: Gout: A Roadmap to Approaches for Improving Global Outcomes Role of Uric Acid Metabolism-Related Inflammation in the Pathogenesis of Metabolic Syndrome Components Such as Atherosclerosis and Nonalcoholic Steatohepatitis A review of uric acid, crystal deposition disease, and gout.Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options Allopurinol initiation and all-cause mortality in the general population.Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes.Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study.Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims.Factors associated with initiation and persistence of urate-lowering therapy.Investigational drugs for hyperuricemia.Xanthine oxidase inhibitors in ischaemic heart disease.Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.Uric acid and cardiovascular risk: What genes can say.Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials.Cardiac and renal protective effects of urate-lowering therapy.Gout and Metabolic Syndrome: a Tangled Web.A meta-analysis of the efficacy of allopurinol in reducing the incidence of myocardial infarction following coronary artery bypass grafting.Association of Gout With Long-Term Cardiovascular Outcomes Among Patients With Obstructive Coronary Artery Disease

P2860

Q26738948-7B166C1C-5DB3-4BF1-AAAD-935A964C95D3 Q26772053-C8BF8DCB-F8B1-4522-AFF0-945B3B10A52D Q26775759-7A201D65-4BDA-40CE-97B0-3BA337995876 Q26778211-D33A9DF6-A43C-421C-B0F9-BB6E9107D3E7 Q28076018-C6F07AF6-2DE7-4AAD-BF53-B68A777BF31A Q28354735-AECF6B54-DDF0-4562-AF47-6CFA628FA661 Q30619265-83DDB5DE-C998-4D72-B041-552306EB13A0 Q33864537-064C66C5-FED4-4148-A174-E31805F58C9A Q34466066-A26001F0-ECA6-4814-9455-CDDAF1BFC005 Q35642254-AC42D88A-66A7-4AF2-AA36-BE8E37C52D91 Q36306524-34738D34-57C5-45E5-9B9D-CFF67C922D9F Q37127097-0F999981-002E-4EB4-B8A8-64D85A9F1DAA Q37251800-4D0A22AA-279C-4A8D-8F18-5DB332487545 Q37308677-C10D6796-179B-436A-9D42-3665B17534D8 Q37589104-FD9DD392-C08E-4AFA-B80B-894BF5648276 Q38527441-30D25C68-6F86-43D1-BD81-0425BC91CB2C Q39324330-10611978-3BC5-4052-908E-A476E0E20B9E Q47594590-6FD8B087-EE3D-4119-898D-80DD47200E07 Q48102504-CA32F7BF-E6CA-4C5C-81BD-724D05B32E46 Q49584618-634F2C0A-88E6-4F19-8BEC-36FA6E1CD83E Q49616077-385BCF71-6E7B-4E75-BFD2-68EDFC6BE0A7 Q52534066-2DAEC7DA-C954-45AC-949F-A33616EA0F35 Q55619193-678BB630-60CF-4772-BA0E-E6BBCFBE660E Q58129718-CFE5CCA7-91F9-4802-9A71-216B32CE88A6

P2860

Impact of allopurinol on risk of myocardial infarction.

http://www.wikidata.org/entity/Q39033643

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Impact of allopurinol on risk of myocardial infarction.

@en

Impact of allopurinol on risk of myocardial infarction.

@nl

type

label

Impact of allopurinol on risk of myocardial infarction.

@en

Impact of allopurinol on risk of myocardial infarction.

@nl

prefLabel

Impact of allopurinol on risk of myocardial infarction.

@en

Impact of allopurinol on risk of myocardial infarction.

@nl

P1433

Q39033643-CED44845-2AE9-48BF-A1C4-8BF6BAA0DA11

P1476

Q39033643-5F3DE436-B22D-47A6-8F44-FF7030CE3410

P2093

Q39033643-72F38707-784A-4347-8060-E524260DEC47

Q39033643-73C57FD7-5A5A-475E-B19F-41772CFDC5CC

Q39033643-79690EA0-450F-45B9-AFE4-6FE711D1D77F

Q39033643-8189A520-C0B9-485B-8BB3-5947827355FD

Q39033643-9EC9D9C7-AD8E-492D-9728-FA56A2749CC5

Q39033643-A595652B-1F1D-4920-A0A6-C2284CB6A7B4

P2860

Q39033643-076F1B81-88AF-4486-87A5-F703FAA84261

Q39033643-078B8DBC-A178-4223-BFB0-88E8B86EC8F6

Q39033643-1D6B9AFE-F6DE-4B61-9DBA-BA13757E2329

Q39033643-1EE38EE1-B133-4E22-A7D7-15BF89D19835

Q39033643-22FC90DB-E6B5-4DD0-8147-9B2C0CCE0E49

Q39033643-37D5FE14-0ACF-4830-A487-A70462B6A397

Q39033643-385686FB-CF52-4EE4-95B0-8E23D777660D

Q39033643-4C88CB27-DDE6-46EE-869A-9813CB9B53FE

Q39033643-4DCB815C-A460-4925-BD61-2F1D794DE0EB

Q39033643-6E4183E6-0F15-4801-8B29-3D302740318C

P304

Q39033643-3328DE4A-441F-40BF-8728-A2FDEFC9140A

P31

Q39033643-0BA83CE8-8A1E-46B0-AD0C-2BB985CDE1EF

P356

Q39033643-04303BDF-2BF8-4DEA-BFA8-5E39A7A395EF

P407

Q39033643-4B138651-7BF6-4725-A355-67021F0A8494

P433

Q39033643-6BC77307-FBDA-4D8F-8031-5E3C0995924D

P478

Q39033643-EDD2A338-F13C-40C7-8524-3E336214AA1A

P50

Q39033643-78B771AB-295A-4073-8328-165596477A81

Q39033643-F8E24753-039F-4646-A803-3BD604411902

P577

Q39033643-D4BBC260-8508-41A3-956E-AF1AE64C582F

P5875

Q39033643-01667928-B5A4-489F-BA6E-235596176B2D

P698

Q39033643-12B07C5B-34CC-4CC6-8183-CABFCAA57387

P921

Q39033643-4F43D44D-8981-4D79-92A3-AC1F6D782A67

Q39033643-C8DD09C1-DF46-415D-A501-88FFC3536584

P356

ANNRHEUMDIS-2012-202972

P1433

Annals of the Rheumatic Diseases

P1476

Impact of allopurinol on risk of myocardial infarction.

@en

P2093

A Alpérovitch

http://www.w3.org/2001/XMLSchema#string

E Aubrun

http://www.w3.org/2001/XMLSchema#string

L Abenhaim

http://www.w3.org/2001/XMLSchema#string

M Rossignol

http://www.w3.org/2001/XMLSchema#string

N Danchin

http://www.w3.org/2001/XMLSchema#string

PGRx MI Group

http://www.w3.org/2001/XMLSchema#string

P2860

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal

Gout and the risk of acute myocardial infarction

Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based Colaus study

Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial.

Colchicine for the treatment of gout.

Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial

Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid.

P304

836-842

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ANNRHEUMDIS-2012-202972

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P50

Pascal Richette

L Grimaldi-Bensouda

P577

2014-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

278409397

http://www.w3.org/2001/XMLSchema#string

P698

24395556

http://www.w3.org/2001/XMLSchema#string

P921